| scholarly article | Q13442814 |
| P50 | author | Andreas Rosenwald | Q28379725 |
| Barbara Serafini | Q64682632 | ||
| P2093 | author name string | Francesca Aloisi | |
| Tobias Derfuss | |||
| Diethilde Theil | |||
| Frank Schrader | |||
| Hartmut Wekerle | |||
| Reinhard Hohlfeld | |||
| Edgar Meinl | |||
| Susan L Kalled | |||
| Markus Krumbholz | |||
| Camelia-Maria Monoranu | |||
| Donna M Hess | |||
| P2860 | cites work | DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF | Q24309087 |
| Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients | Q24563395 | ||
| BCMA is essential for the survival of long-lived bone marrow plasma cells | Q28587037 | ||
| B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells | Q28590517 | ||
| The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers | Q35834899 | ||
| Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis | Q36351504 | ||
| Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction | Q36368672 | ||
| Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. | Q37285430 | ||
| Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. | Q37385073 | ||
| B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions | Q41697260 | ||
| G-CSF-stimulated neutrophils are a prominent source of functional BLyS | Q41818295 | ||
| Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells | Q42079747 | ||
| Astrocyte cultures from human embryonic brain: characterization and modulation of surface molecules by inflammatory cytokines | Q42453393 | ||
| Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. | Q44223059 | ||
| Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. | Q44471579 | ||
| Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis | Q47274470 | ||
| Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
| Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. | Q47817146 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. | Q54759503 | ||
| TNF Deficiency Fails to Protect BAFF Transgenic Mice against Autoimmunity and Reveals a Predisposition to B Cell Lymphoma | Q57212187 | ||
| Synthesis and release of B-lymphocyte stimulator from myeloid cells | Q73335981 | ||
| Primary central nervous system lymphoma | Q77754938 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| nervous system | Q9404 | ||
| central nervous system lymphoma | Q136312 | ||
| astrocyte | Q502961 | ||
| primary central nervous system lymphoma | Q3246818 | ||
| P304 | page(s) | 195-200 | |
| P577 | publication date | 2005-01-17 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma | |
| P478 | volume | 201 |
| Q40185060 | A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis |
| Q90727923 | APRIL and BAFF: novel biomarkers for central nervous system lymphoma |
| Q33418752 | APRIL is overexpressed in cancer: link with tumor progression |
| Q55052878 | Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines. |
| Q37237410 | Advances in the understanding of the mechanism of action of IVIg |
| Q33584291 | Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-beta-dependent mechanism |
| Q103034460 | Altered astrocytic function in experimental neuroinflammation and multiple sclerosis |
| Q43881975 | Amelioration of experimental autoimmune encephalomyelitis by BLyS autovaccine. |
| Q28593440 | An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation |
| Q36484465 | Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials |
| Q38975695 | Anti-CD20 monoclonal antibodies in multiple sclerosis |
| Q37597818 | Astrocyte barriers to neurotoxic inflammation |
| Q36878427 | Astrocytes--friends or foes in multiple sclerosis? |
| Q38966132 | Astrocytes: Integrative Regulators of Neuroinflammation in Stroke and Other Neurological Diseases |
| Q24628925 | Atacicept: targeting B cells in multiple sclerosis |
| Q38961202 | B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. |
| Q38884402 | B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease |
| Q26770664 | B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions |
| Q26801386 | B Cells and Autoantibodies in Multiple Sclerosis |
| Q37093281 | B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity |
| Q42984862 | B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia |
| Q104479846 | B cell depletion therapies in autoimmune disease: advances and mechanistic insights |
| Q34896699 | B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome |
| Q38702111 | B cell-directed therapies in multiple sclerosis |
| Q38050398 | B cells and antibodies in multiple sclerosis pathogenesis and therapy |
| Q35903957 | B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases |
| Q42249555 | B cells as a target of immune modulation |
| Q37278022 | B cells as therapeutic targets in autoimmune neurological disorders |
| Q38212081 | B cells in MS and NMO: pathogenesis and therapy |
| Q91236273 | B cells in autoimmune and neurodegenerative central nervous system diseases |
| Q48321634 | B cells in multiple sclerosis |
| Q38207564 | B cells in multiple sclerosis: good or bad guys?: An article for 28 May 2014 - World MS Day 2014. |
| Q34544062 | B cells move to centre stage: novel opportunities for autoimmune disease treatment |
| Q37009908 | B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation |
| Q61816706 | B-cell activating factor receptor expression is associated with germinal center B-cell maintenance |
| Q57041869 | B-cell subsets: cellular interactions and relevance in multiple sclerosis |
| Q45385575 | B-cell-activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNA-activated protein kinase activation |
| Q49208897 | BAFF and APRIL expression as an autoimmune signature of membranous nephropathy |
| Q34245983 | BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus |
| Q37844764 | BAFF inhibition: a new class of drugs for the treatment of autoimmunity |
| Q36925946 | BAFF is increased in renal transplant patients following treatment with alemtuzumab |
| Q54314206 | BAFF levels are increased in lesional skin and sera in patients with cutaneous T-cell lymphoma. |
| Q34012753 | BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis |
| Q21564037 | BAFF, APRIL, TWE-PRIL: Who's who? |
| Q30724766 | BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 proteins are related to human glioma tumor grade: immunohistochemistry and public microarray data meta-analysis |
| Q80059855 | BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer |
| Q36722422 | BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy |
| Q37593590 | BAFF: a local and systemic target in autoimmune diseases |
| Q34084521 | BLyS and APRIL in rheumatoid arthritis |
| Q38799791 | Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser |
| Q36260857 | Blockade of B-cell activating factor with TACI-IgG effectively reduced Th1 and Th17 cells but not memory T cells in experimental allergic encephalomyelitis mice |
| Q46275246 | CNS viral infection diverts homing of antibody-secreting cells from lymphoid organs to the CNS. |
| Q64900086 | CSF TACI and BAFF levels in patients with primary CNS lymphoma as novel diagnostic biomarkers. |
| Q36161486 | CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation |
| Q90706043 | Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS? |
| Q92712543 | Central Nervous System Inflammatory Aggregates in the Theiler's Virus Model of Progressive Multiple Sclerosis |
| Q21144285 | Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis |
| Q58190179 | Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus |
| Q35850791 | Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome |
| Q48701331 | Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment |
| Q24273331 | Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases |
| Q98177385 | Connecting Immune Cell Infiltration to the Multitasking Microglia Response and TNF Receptor 2 Induction in the Multiple Sclerosis Brain |
| Q37517172 | Cracking the BAFF code. |
| Q26771459 | Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis |
| Q34886336 | Cytokines and perinatal brain damage |
| Q36535669 | Death ligands and autoimmune demyelination |
| Q47102132 | Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function |
| Q37328280 | Disease-modifying agents for multiple sclerosis: recent advances and future prospects |
| Q36229219 | Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain |
| Q39737347 | Effect of vitamin D(3) supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis |
| Q28248398 | Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease |
| Q36220379 | Elevated BAFF levels in the cerebrospinal fluid of patients with neuro-Behçet's disease: BAFF is correlated with progressive dementia and psychosis |
| Q64076437 | Emerging small-molecule treatments for multiple sclerosis: focus on B cells |
| Q47546882 | Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells |
| Q33599648 | Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation |
| Q37348896 | Expression and localization of rabbit B-cell activating factor (BAFF) and its specific receptor BR3 in cells and tissues of the rabbit immune system |
| Q40957585 | Expression of B-cell activating factor, a proliferating inducing ligand and its receptors in primary central nervous system lymphoma |
| Q34742821 | Factors supporting intrathecal humoral responses following viral encephalomyelitis. |
| Q28535303 | Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis |
| Q41576345 | Fingolimod induces neuroprotective factors in human astrocytes |
| Q28581828 | Functional implication of BAFF synthesis and release in gangliosides-stimulated microglia |
| Q38081955 | Glia-based biomarkers and their functional role in the CNS. |
| Q36919822 | Glial cell activation, recruitment, and survival of B-lineage cells following MCMV brain infection |
| Q48138391 | Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement. |
| Q52577393 | Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis. |
| Q37785326 | Humoral autoimmunity in multiple sclerosis |
| Q26865971 | Humoral-targeted immunotherapies in multiple sclerosis |
| Q39851981 | Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor. |
| Q36934308 | Immune opsonins modulate BLyS/BAFF release in a receptor-specific fashion |
| Q27686768 | Immunomodulatory activity of interferon-beta |
| Q36577275 | Immunopathogenesis and immunotherapy of multiple sclerosis |
| Q55039421 | Immunophenotypic characterization of CSF B cells in virus-associated neuroinflammatory diseases. |
| Q57470698 | Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis |
| Q39635585 | Induction of B Cell-Activating Factor by Viral Infection Is a General Phenomenon, but the Types of Viruses and Mechanisms Depend on Cell Type |
| Q50702854 | Innate defense regulator peptide 1018 protects against perinatal brain injury. |
| Q40527857 | Interferon gamma modulation of disease manifestation and the local antibody response to alphavirus encephalomyelitis |
| Q34141439 | Intrarenal production of B-cell survival factors in human lupus nephritis |
| Q38084075 | Intrathecal humoral immunity to encephalitic RNA viruses. |
| Q27334562 | Investigation of encephalopathy caused by Shiga toxin 2c-producing Escherichia coli infection in mice |
| Q48695171 | Investigation of magnetization transfer ratio-derived pial and subpial abnormalities in the multiple sclerosis spinal cord |
| Q43183915 | LOTUS, a potent blocker of Nogo receptor-1 causing inhibition of axonal growth |
| Q37186200 | Lymphoid chemokines in chronic neuroinflammation |
| Q36405080 | Lymphoid neogenesis in chronic inflammatory diseases. |
| Q34434727 | MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts |
| Q27021535 | Molecular pathogenesis of neuromyelitis optica |
| Q36269623 | Molecules involved in T-B co-stimulation and B cell homeostasis: possible targets for an immunological intervention in autoimmunity |
| Q37968620 | Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. |
| Q84390184 | Multiple sclerosis: human model for EAE? |
| Q53837559 | Neuroimmunology: B cells and variant BAFF in autoimmune disease. |
| Q28080620 | Neuroinflammation: Ways in Which the Immune System Affects the Brain |
| Q34896464 | No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome |
| Q37313911 | Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary |
| Q37781515 | Nuclear Receptors, Inflammation, and Neurodegenerative Diseases |
| Q38665518 | Ocrelizumab: a B-cell depleting therapy for multiple sclerosis |
| Q26739719 | Oligodendrocyte, Astrocyte, and Microglia Crosstalk in Myelin Development, Damage, and Repair |
| Q50072806 | Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon |
| Q33673190 | Permissive environment for B‐cell maturation in myositis muscle in the absence of B‐cell follicles |
| Q45372213 | Plasma cells in the central nervous system in the Theiler's virus model of multiple sclerosis |
| Q34409447 | Practical considerations on the use of rituximab in autoimmune neurological disorders |
| Q34059107 | Progression from IgD+ IgM+ to isotype-switched B cells is site specific during coronavirus-induced encephalomyelitis. |
| Q41933450 | Protective Humoral Immunity in the CNS Requires Peripheral CD19-Dependent Germinal Center Formation Following Coronavirus Encephalomyelitis. |
| Q36955326 | Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms |
| Q89171079 | Reassessing B cell contributions in multiple sclerosis |
| Q36868426 | Recent advances in the neuropathology of multiple sclerosis |
| Q36607157 | Recruitment and retention of B cells in the central nervous system in response to alphavirus encephalomyelitis |
| Q30606953 | Regulatory mechanisms of testosterone-stimulated song in the sensorimotor nucleus HVC of female songbirds. |
| Q64228473 | Reverse Signaling of Tumor Necrosis Factor Superfamily Proteins in Macrophages and Microglia: Superfamily Portrait in the Neuroimmune Interface |
| Q36832863 | Role of B cells in pathogenesis of multiple sclerosis |
| Q42437564 | Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity |
| Q89589416 | Role of Nuclear factor kappa B (NF-κB) Signalling in Neurodegenerative Diseases: An Mechanistic Approach |
| Q38384621 | Role of the innate and adaptive immune responses in the course of multiple sclerosis |
| Q41594953 | Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis |
| Q40623713 | Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients |
| Q50638113 | Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma. |
| Q38163336 | Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice |
| Q79415993 | TACI attenuates antibody production costimulated by BAFF-R and CD40 |
| Q36761844 | Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges |
| Q99557580 | Targeting co-stimulatory molecules in autoimmune disease |
| Q36474316 | The B cell response in multiple sclerosis |
| Q38194895 | The BAFF/APRIL system in SLE pathogenesis. |
| Q38107660 | The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity |
| Q39122022 | The Interplay of IL-21 and BAFF in the Formation and Maintenance of Human B Cell Memory |
| Q37981918 | The Nogo-66 receptor family in the intact and diseased CNS. |
| Q26782843 | The Role of Astrocytes in Multiple Sclerosis Progression |
| Q52668332 | The Role of Astrocytes in Multiple Sclerosis. |
| Q96304646 | The Role of BAFF-R Signaling in the Growth of Primary Central Nervous System Lymphoma |
| Q47116115 | The chronically inflamed central nervous system provides niches for long-lived plasma cells |
| Q92213495 | The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis |
| Q37052820 | The development of primary central nervous system B-cell lymphoma in multiple sclerosis |
| Q51976061 | The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis. |
| Q34810293 | The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity |
| Q24597958 | The innate immune system in demyelinating disease |
| Q37818131 | The potential role of B cell-targeted therapies in multiple sclerosis |
| Q37181308 | The relation between inflammation and neurodegeneration in multiple sclerosis brains. |
| Q92302527 | The role of B cells in multiple sclerosis: Current and future therapies |
| Q36736188 | The target tissue in autoimmunity--an influential niche |
| Q38800522 | Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis |
| Q42107547 | Therapeutic effects of PADRE-BAFF autovaccine on rat adjuvant arthritis. |
| Q57464040 | Therapeutic spectrum of interferon-β in ischemic stroke |
| Q39058405 | Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination. |
| Q37737305 | Treating multiple sclerosis with monoclonal antibodies: a 2010 update. |
| Q36380499 | Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity |
| Q35463552 | Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets |
| Q41941241 | Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways |
| Q40273988 | What do we know about the role of regulatory B cells (Breg) during the course of infection of two major parasitic diseases, malaria and leishmaniasis? |
| Q59137584 | White-matter repair: Interaction between oligodendrocytes and the neurovascular unit |
| Q51890165 | [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis]. |
| Q83274218 | [Rituximab in treatment for neuroimmunological diseases] |
| Q51958899 | [Targeting B cells in multiple sclerosis. Current concepts and strategies]. |
| Q80434989 | [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis] |
| Q35814239 | γ-Secretase directly sheds the survival receptor BCMA from plasma cells |
Search more.